Posted 3/15/2023
Severe forms of neurofibromatosis linked to disruptions in a protein partnership New research by Frederick National...
Posted 2/15/2023
To celebrate International Women and Girls in Science Day, we co-hosted a panel discussion on Feb. 10 with Woman to...
Posted 11/15/2022
The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer...
All News
RAS Initiative: An ambitious model eight years in
RAS InitiativePosted 8/3/2021Across the world, conferencing software flicked open on computer screens. It was 8 a.m. in San Francisco, 11 a.m. in Frederick, 5 p.m. in Madrid, 11 p.m. in Hong Kong. The first day of the Third National Cancer Institute RAS Initiative Symposium was about to begin. Time zones notwithstanding, scientists and onlookers were tuning in from offices, studies, and living rooms to…
Study shows disruption to cancer screenings during initial wave of COVID-19 pandemic
Clinical Monitoring Research ProgramPosted 7/26/2021The initial response to the COVID-19 pandemic disrupted cancer screenings as it caused many countries to suspend services following government guidance and to reallocate screening resources, a new study shows.
“The full impact of the suspension of the screening and what this dynamic is going to mean in cancer in general is still to be seen,” said Douglas Puricelli Perin,…
Collaborative study puts Chernobyl hereditary mutation fears to rest
Posted 7/13/2021Cleanup workers and others exposed to radiation from the Chernobyl nuclear accident in 1986 are unlikely to pass any genetic damage on to future generations, according to a new study.
“This is good news for the people of Eastern Europe,” said Frederick National Laboratory scientist Meredith Yeager, first author on the multi-institutional study led by Stephen Chanock of the…
Partnership seeks to develop KRAS degraders for cancer therapy
Partnership Development Office, RAS InitiativePosted 6/22/2021The Frederick National Laboratory for Cancer Research and biotech company Progenra, Inc., recently signed a contractor Cooperative Research and Development Agreement (cCRADA) to develop a novel therapy that could be capable of degrading KRAS.
The human KRAS gene is one of the most elusive and potentially promising cancer therapy targets. KRAS mutations drive multiple…
Genetic twist helps explain unique properties of promising AIDS vaccine
AIDS and Cancer Virus ProgramPosted 5/27/2021While a unique AIDS vaccine approach had previously shown an encouraging and unprecedented kind of protection against AIDS virus infection in nonhuman primate models, the underlying mechanism for this distinctive form of vaccine protection has remained unclear – until now. New research has provided important insights into understanding how the promising vaccine works.…
VRC01 HIV antibody falls short in trials, but don’t discount antibodies yet
Vaccine Clinical Materials ProgramPosted 5/20/2021An anti-HIV antibody called VRC01 does not protect people from acquiring HIV, according to findings from the Antibody-Mediated Prevention (AMP) Trials.
The results were recently reported in the New England Journal of Medicine. While they indicate that this antibody alone is not a strong HIV-prevention measure, the data suggest that antibodies remain a potentially viable…
FNL partnership with LSU Health New Orleans to investigate links between obesity and lung cancer
Partnership Development OfficePosted 5/13/2021While the link between certain conditions and cancer risk, such as tobacco smoke exposure and lung cancer, has been firmly established, for other conditions, the association and the biological mechanisms behind them remain murky.
To this end, the Frederick National Laboratory for Cancer Research (FNL) and Louisiana State University (LSU) Health Sciences Center New Orleans…
AIDS research team aims to push boundaries in science and beyond
AIDS and Cancer Virus ProgramPosted 4/29/2021Researchers are launching a new project aimed at understanding vaginal transmission of HIV and examining what happens in the earliest stages of infection in people with a cervix, who represent about one-fifth of new cases each year.
Christine Fennessey, Ph.D. and Claire Deleage, Ph.D. in the Frederick National Laboratory’s AIDS and Cancer Virus Program received funding…
BRMP, Bastion of Progress, Resonates Decades Later
Posted 4/26/2021Though it lasted just 15 years, Frederick’s first clinical oncology program answered multiple fundamental questions in the fledgling field of immunotherapy and primed the local medical community to become the oncology research hub it is today. The Biological Response Modifiers Program (BRMP) received formal recognition from the Department of Health and Human Services 40 years…
Study ‘sheds light’ on critical step in RAS-driven cancers
RAS InitiativePosted 4/21/2021Results of a recent study suggest how two oncogenic proteins—KRAS and RAF kinase—interact, and the structure of this protein-protein complex provides a blueprint for designing new inhibitors that could help prevent RAS-driven cancers.
The KRAS gene provides instructions for making the KRAS protein that is part of a signaling pathway. The protein relays signals from…
Media Inquiries
For all media related questions please contact:
Mary Ellen Hackett
Manager, Communications Office